• Kai-Jin Cai, Shi-Qing Su, Yao-Guo Wang, and Yi-Ming Zeng.
• From the Departments of Emergency.
• Pediatr Emerg Care. 2021 Dec 1; 37 (12): e1139e1144e1139-e1144.

ObjectiveThis study evaluates the efficacy and tolerability of dexamethasone (DEX) as an alternative to prednisone/prednisolone (PRED) for the treatment of pediatric asthma exacerbations in emergency department (ED).MethodsFixed-effects meta-analyses of selected endpoints were performed by using data taken from relevant studies identified by following a priori eligibility criteria after a comprehensive literature search in several electronic databases.ResultsData from 10 studies (3208 pediatric asthma patients [1616 DEX treated and 1592 PRED treated], 4.77 years [95% confidence interval, 3.80-5.56 years], 63% [57.76%-62.68%] males) were used. Risk of vomiting drug was significantly lower in DEX group than in PRED group (risk ratio, 0.29 [0.18-0.48]; P ˂ 0.00001). Emergency department stay between DEX and PRED treated patients was statistically different (0.16 [0.03-0.40] hours; P = 0.02) but may not be clinically meaningful. The number of β-agonist therapies received by DEX- and PRED-treated patients was similar. Treatments with both DEX and PRED were associated with improvement in asthma status assessment scores, and there was no significant difference between the groups. There were also no differences between the groups in hospitalization rate, ED revisit rate, and hospital admission rate after relapse.ConclusionsDexamethasone is a suitable alternative to PRED for the treatment of pediatric asthma exacerbation in ED.Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

18 keywords...

hide…